FDA Grants Orphan Drug Status to NNZ-2591 for Newborn Brain Injury

Neuren Pharmaceuticals has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for NNZ-2591, a potential treatment for neonatal hypoxic-ischemic encephalopathy (HIE). HIE is a severe brain injury affecting newborns, and this designation provides incentives for developing therapies for rare conditions.